BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 25363767)

  • 1. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
    Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
    Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-canonical genomic driver mutations of urethane carcinogenesis.
    Li S; Counter CM
    PLoS One; 2022; 17(4):e0267147. PubMed ID: 35482806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.
    McFadden DG; Politi K; Bhutkar A; Chen FK; Song X; Pirun M; Santiago PM; Kim-Kiselak C; Platt JT; Lee E; Hodges E; Rosebrock AP; Bronson RT; Socci ND; Hannon GJ; Jacks T; Varmus H
    Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6409-E6417. PubMed ID: 27702896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities.
    Kerr EM; Gaude E; Turrell FK; Frezza C; Martins CP
    Nature; 2016 Mar; 531(7592):110-3. PubMed ID: 26909577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a.
    Fujimoto J; Nunomura-Nakamura S; Liu Y; Lang W; McDowell T; Jakubek Y; Ezzeddine D; Kapere Ochieng J; Petersen J; Davies G; Fukuoka J; Wistuba II; Ehli E; Fowler J; Scheet P; Kadara H
    Int J Cancer; 2017 Oct; 141(8):1589-1599. PubMed ID: 28653505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive genomic instability in the FVB/Kras(LA2) mouse model of lung cancer.
    To MD; Quigley DA; Mao JH; Del Rosario R; Hsu J; Hodgson G; Jacks T; Balmain A
    Mol Cancer Res; 2011 Oct; 9(10):1339-45. PubMed ID: 21807965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased tumorigenesis in mice with a Kras point mutation at C118.
    Huang L; Carney J; Cardona DM; Counter CM
    Nat Commun; 2014 Nov; 5():5410. PubMed ID: 25394415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
    To MD; Rosario RD; Westcott PM; Banta KL; Balmain A
    Oncogene; 2013 Aug; 32(34):4028-33. PubMed ID: 22945650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PKC
    Garg R; Cooke M; Benavides F; Abba MC; Cicchini M; Feldser DM; Kazanietz MG
    Cancer Res; 2020 Dec; 80(23):5166-5173. PubMed ID: 32994205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden.
    Salehi-Rad R; Li R; Tran LM; Lim RJ; Abascal J; Momcilovic M; Park SJ; Ong SL; Shabihkhani M; Huang ZL; Paul M; Shackelford DB; Krysan K; Liu B; Dubinett SM
    Cancer Immunol Immunother; 2021 Aug; 70(8):2389-2400. PubMed ID: 33507343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Kras mutational spectra of chemically induced lung tumors in different inbred mice mimics the spectra of KRAS mutations in adenocarcinomas in smokers versus nonsmokers.
    Fritz JM; Dwyer-Nield LD; Russell BM; Malkinson AM
    J Thorac Oncol; 2010 Feb; 5(2):254-7. PubMed ID: 20101149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoform-Specific Effects of Wild-Type Ras Genes on Carcinogen-Induced Lung Tumorigenesis in Mice.
    Weyandt JD; Carney JM; Pavlisko EN; Xu M; Counter CM
    PLoS One; 2016; 11(12):e0167205. PubMed ID: 27911940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
    Green S; Trejo CL; McMahon M
    Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signaling levels mold the RAS mutation tropism of urethane.
    Li S; Counter CM
    Elife; 2021 May; 10():. PubMed ID: 33998997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer.
    Tessema M; Yingling CM; Snider AM; Do K; Juri DE; Picchi MA; Zhang X; Liu Y; Leng S; Tellez CS; Belinsky SA
    J Thorac Oncol; 2014 Jun; 9(6):784-93. PubMed ID: 24807155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of Sprouty 2 in mouse lung epithelium inhibits urethane-induced tumorigenesis.
    Minowada G; Miller YE
    Am J Respir Cell Mol Biol; 2009 Jan; 40(1):31-7. PubMed ID: 18635814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Point mutation of K-ras gene in cisplatin-induced lung tumours in A/J mice.
    Hisamoto A; Kondo E; Kiura K; Okada T; Hosokawa S; Mimoto J; Takigawa N; Tabata M; Tanimoto M
    Lung Cancer; 2007 Oct; 58(1):15-20. PubMed ID: 17604873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic and transcriptional alterations in lung adenocarcinoma in relation to EGFR and KRAS mutation status.
    Planck M; Edlund K; Botling J; Micke P; Isaksson S; Staaf J
    PLoS One; 2013; 8(10):e78614. PubMed ID: 24205279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational landscape of a chemically-induced mouse model of liver cancer.
    Connor F; Rayner TF; Aitken SJ; Feig C; Lukk M; Santoyo-Lopez J; Odom DT
    J Hepatol; 2018 Oct; 69(4):840-850. PubMed ID: 29958939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung.
    Maeda Y; Tsuchiya T; Hao H; Tompkins DH; Xu Y; Mucenski ML; Du L; Keiser AR; Fukazawa T; Naomoto Y; Nagayasu T; Whitsett JA
    J Clin Invest; 2012 Dec; 122(12):4388-400. PubMed ID: 23143308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.